Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Astellas Pharma Inc (OP: ALPMY ) 12.32 +0.35 (+2.92%) Streaming Delayed Price Updated: 3:58 PM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Astellas Pharma Inc < Previous 1 2 3 Next > Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data August 05, 2024 Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... Via Benzinga MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential February 22, 2024 MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. Via Talk Markets Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal December 31, 2023 Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program.... Via Talk Markets Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 December 29, 2023 According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. Via Benzinga How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks October 22, 2023 The companies studied a combination of Keytruda and Padcev in bladder cancer patients. Via Investor's Business Daily Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study October 05, 2023 Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant... Via Benzinga Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years September 24, 2023 The multibillionaire's portfolio features some moneymaking ideas. Via The Motley Fool Why Is Seagen Stock Trading Higher Today? September 22, 2023 Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: Via Benzinga Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer September 22, 2023 The companies tested a key combination in patients with previously untreated bladder cancer. Via Investor's Business Daily What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? September 20, 2023 Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected Via Benzinga How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? September 01, 2023 Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. Via MarketBeat Topics Economy Exposures Interest Rates Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin August 07, 2023 The company is already under scrutiny after reports of side effects tied to Syfovre. Via Investor's Business Daily From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs July 07, 2023 Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... Via Benzinga Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas June 17, 2023 Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates... Via Talk Markets Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles June 08, 2023 Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as Via Benzinga The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree June 02, 2023 Big Pharma is facing a patent cliff that could siphon off billions in revenue. Via Investor's Business Daily Why Shares of Annexon Are Plummeting Thursday May 25, 2023 Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. Via The Motley Fool Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories May 15, 2023 Bloomberg Via Benzinga Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback May 15, 2023 The FDA on Friday approved Japanese drugmaker Astellas Pharma Inc’s (OTC: ALPMY) (OTC: ALPMF) Veozah (fezolinetant) for hot flashes Via Benzinga Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today May 01, 2023 These three biotech stocks were on the volatile side today. Via The Motley Fool Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58% May 01, 2023 Astellas Pharma Inc (OTC: ALPMY) and Pfizer Inc (NYSE: PFE) announced Via Benzinga Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma May 01, 2023 The company is working on a treatment for the eye disease known as geographic atrophy. Via Investor's Business Daily First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories May 01, 2023 Benzinga Via Benzinga Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move May 01, 2023 Stocks have reverted to their cautious ways on Monday amid a slew of market-moving catalysts. Via Benzinga Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration' May 01, 2023 Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of Via Benzinga FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer April 04, 2023 Via Benzinga Japanese Government Urges China To Release Astellas Pharma's Employee March 27, 2023 The Japanese government is reportedly seeking the release of an employee of Japanese pharma company Astellas Pharma Inc (OTC: ALPMF), detained by Chinese authorities. The reasons why the person was... Via Benzinga Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug March 17, 2023 Via Benzinga Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation March 13, 2023 Via Benzinga 'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover February 27, 2023 The potential deal follows rumors last year that Merck could buy Seagen. Via Investor's Business Daily < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
